Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information
Elite Pharmaceuticals (OTCQB:ELTP) reported strong financial results for Q1 FY2026 ended June 30, 2025. The company achieved consolidated revenues of $40.2 million, marking a significant 114% increase compared to the same period last year. Operating profits surged to $21.7 million, representing a remarkable 462% growth year-over-year.
The exceptional performance was primarily driven by the successful launch of Elite's lisdexamfetamine products and robust growth across the Elite label product lines. The company has scheduled a conference call for August 15, 2025, at 11:30 AM EDT to discuss these results and provide business updates.
Elite Pharmaceuticals (OTCQB:ELTP) ha registrato risultati finanziari robusti per il primo trimestre dell'esercizio 2026 conclusosi il 30 giugno 2025. La società ha conseguito ricavi consolidati per 40,2 milioni di dollari, con un incremento significativo del 114% rispetto allo stesso periodo dell'anno precedente. I profitti operativi sono saliti a 21,7 milioni di dollari, segnando una crescita notevole del 462% su base annua.
Queste performance eccezionali sono state trainate principalmente dal lancio riuscito dei prodotti a base di lisdexamfetamina di Elite e dalla solida crescita delle linee di prodotti a marchio Elite. La società ha programmato una conference call per il 15 agosto 2025 alle 11:30 AM EDT per discutere i risultati e fornire aggiornamenti sull'attività.
Elite Pharmaceuticals (OTCQB:ELTP) informó sólidos resultados financieros del primer trimestre del ejercicio 2026, finalizado el 30 de junio de 2025. La compañía alcanzó ingresos consolidados de 40,2 millones de dólares, lo que supone un aumento significativo del 114% respecto al mismo período del año anterior. Las ganancias operativas se dispararon hasta 21,7 millones de dólares, representando un notable crecimiento interanual del 462%.
El rendimiento excepcional se debió principalmente al exitoso lanzamiento de los productos de lisdexanfetamina de Elite y al fuerte crecimiento de las líneas de productos con marca Elite. La empresa ha programado una conferencia telefónica para el 15 de agosto de 2025 a las 11:30 AM EDT para comentar estos resultados y ofrecer actualizaciones del negocio.
Elite Pharmaceuticals (OTCQB:ELTP)는 2025년 6월 30일로 종료된 2026 회계연도 1분기 실적에서 견조한 성과를 보고했습니다. 회사는 연결 매출 4,020만 달러를 기록했으며 이는 전년 동기 대비 114% 증가2,170만 달러로 급증하여 전년 대비 462% 증가를 보였습니다.
이 같은 탁월한 실적은 주로 Elite의 리스덱삼페타민(lisdexamfetamine) 제품 성공적 출시와 Elite 브랜드 제품군의 강한 성장에 기인합니다. 회사는 2025년 8월 15일 오전 11시 30분(동부 시간) 회계 실적 및 사업 업데이트를 위한 콘퍼런스 콜을 예정하고 있습니다.
Elite Pharmaceuticals (OTCQB:ELTP) a annoncé de solides résultats financiers pour le premier trimestre de l'exercice 2026 clos le 30 juin 2025. La société a réalisé des revenus consolidés de 40,2 millions de dollars, soit une hausse significative de 114% par rapport à la même période de l'année précédente. Les bénéfices d'exploitation ont grimpé à 21,7 millions de dollars, représentant une croissance remarquable de 462% en glissement annuel.
Cette performance exceptionnelle a été principalement portée par le lancement réussi des produits à base de lisdexamfétamine d'Elite et par la forte croissance des gammes de produits sous la marque Elite. La société a planifié une conférence téléphonique le 15 août 2025 à 11h30 EDT pour commenter ces résultats et fournir des mises à jour sur ses activités.
Elite Pharmaceuticals (OTCQB:ELTP) meldete starke Finanzergebnisse für das erste Quartal des Geschäftsjahres 2026, das am 30. Juni 2025 endete. Das Unternehmen erzielte konsolidierte Umsätze von 40,2 Mio. USD, was einem deutlichen Anstieg von 114% gegenüber dem Vorjahreszeitraum entspricht. Das Betriebsergebnis stieg auf 21,7 Mio. USD und verzeichnete damit ein bemerkenswertes Wachstum von 462% im Jahresvergleich.
Die außergewöhnliche Leistung wurde hauptsächlich durch die erfolgreiche Markteinführung der Lisdexamfetamin-Produkte von Elite und das starke Wachstum der Elite-Produktlinien getrieben. Das Unternehmen hat eine Telefonkonferenz für den 15. August 2025 um 11:30 Uhr EDT angekündigt, um diese Ergebnisse zu besprechen und geschäftliche Updates zu geben.
- Revenue grew 114% year-over-year to $40.2 million
- Operating profits increased 462% to $21.7 million
- Successful launch of new lisdexamfetamine products
- Strong growth across Elite label product lines
- None.
Conference Call Scheduled for Friday, August 15 at 11:30 AM EDT
Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2026 ended June 30, 2025 ("First Quarter").
Consolidated revenues for the three-month period ending June 30, 2025, were
Conference Call Information
Elite's management will host a conference call to discuss the First Quarter of Fiscal Year 2026 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.
| Date: | August 15, 2025 |
| Time: | 11:30 AM EDT |
| Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 |
| Questions: | dianne@elitepharma.com Financial questions by 7:00 PM EDT on Thursday, August 14, 2025 |
| Audio Replay: | https://elite.irpass.com/events_presentations |
The financial statements can be viewed for Elite's First Quarter of Fiscal Year 2026 on Form 10-Q here.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing, manufacturing, and distributing oral, controlled-release drug products. Elite owns multiple generic products, which it distributes nationally under the Elite Laboratories, Inc. label. Elite also has products licensed to TAGI Pharma. Elite operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262400
FAQ
What were Elite Pharmaceuticals (ELTP) Q1 FY2026 earnings?
How much did Elite Pharmaceuticals' revenue grow in Q1 2026?
What drove Elite Pharmaceuticals' growth in Q1 FY2026?
When is Elite Pharmaceuticals' Q1 2026 earnings call?
